Future Cancer Diagnostic Technologies and Market Applications

December 2011 | 110 pages | ID: CB1AB9D70A8EN
Venture Planning Group

Abstracts

This report provides detailed assessments of such technologies as monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.

Contains 110 pages

Contents

CURRENT AND EMERGING TECHNOLOGIES

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
  a. Technological Principle
  b. Radioimmunoassay (RIA)
  c. Enzyme Immunoassays (EIA)
    - Overview
    - ELISA
    - Immunofiltration
    - Particle-Membrane Capture Immunoassay
    - Enzyme Amplification
  d. Fluorescent Immunoassays
  e. Luminescence
    - Chemiluminescence
    - Bioluminescence
3. Molecular Diagnostics
  a. Technology Overview
  b. Amplification Methods
    - PCR
    - DAP-PCR
    - Immuno-PCR
    - QC-PCR
    - CAR
    - DNA
    - HPA
    - LCR
    - NASBA
    - QBR
    - SDA
    - 3 SR, and others
4. Biochips/Microarrays
5. Chromosome Analysis
  a. Chronic Myelogenous Leukemia (CML)
  b. Acute Myeloid Leukemia (AML)
  c. Acute Lymphoblastic Leukemia (ALL)
  d. Malignant Lymphomas
    Lymphoid Malignancies
  e. Chronic Lymphocytic Leukemia (CLL)
  f. Solid Cancers
  g. Chromosomal Translocation and Oncogenes
6. Microcomputers and Automation
7. Artificial Intelligence
8. Flow Cytometry
9. Biosensors

E. COMPETING/COMPLEMENTING TECHNOLOGIES

1. CT
2. MRI
3. NMR
4. PET
5.Photonics Spectroscopy